tiprankstipranks
Trending News
More News >

MaxCyte Announces AIM Delisting to Focus on NASDAQ

Story Highlights
MaxCyte Announces AIM Delisting to Focus on NASDAQ

Confident Investing Starts Here:

MaxCyte ( (MXCT) ) just unveiled an update.

MaxCyte, Inc. has announced its intention to cancel the trading of its ordinary shares on AIM, with plans to file a definitive proxy statement to seek stockholder approval for this delisting. The company aims to focus on its NASDAQ listing, and the move is part of a strategic decision to streamline its market presence, potentially impacting stakeholders by concentrating trading activities on a single exchange.

More about MaxCyte

MaxCyte, Inc. is a leading company in the cell engineering industry, providing platform technologies that advance the discovery, development, and commercialization of next-generation cell therapeutics. Their ExPERT platform, based on Flow Electroporation technology, supports the expanding cell therapy market and includes a range of instruments and proprietary processing assemblies.

YTD Price Performance: -34.57%

Average Trading Volume: 34,074

Technical Sentiment Signal: Buy

Current Market Cap: £230.5M

Learn more about MXCT stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App